Alfin Inc &lt;AFN> said it has received aregulatory letter from the Office of Compliance of the U.S.Food and Drug Administration asserting that because oflabelling and certain advertising claims its Glycel productsare "new drugs" within the meaning of the Federal Food, Drugand Cosmetic Act for which no approval has been obtained andare "misbranded" in their labelling.    The company said it understands that this action is part ofan industry-wide investigation.    The company added it is reviewing the matter with counsel,intends to respond and take corrective action, if necessary. Reuter&#3;